precision medicine

Using innovative organoid biotechnology, miniature tumors (mini-tumors or organoids) are recreated in the laboratory using tumor stem cells collected from patients diagnosed with breast cancer. They are expanded, characterized at the molecular level, and collected in the Breast Cancer Tissues & Organoids (BCTO) biobank (https://www.igb.cnr.it/index.php/bcto-biobank/) along with the tissue samples from which they were generated.

NANOINCICLO is a technology based on the use of nanostructured cyclodextrins (CDs) for the targeted delivery of drugs such as anticancer drugs, photodynamic drugs, anti-inflammatories, antivirals, antibacterials, nutraceuticals and metals with therapeutic and diagnostic properties. Successful CDs for the proposed technology are FDA-approved or in advanced pre-clinical investigational stage and include natural and functionalized, polymeric, and amphiphilic monomeric CDs.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).